IP Library Granted Patent US 8,114,838
Granted Patent B2
US 8,114,838 · App. 11/085,812 · Granted Feb 14, 2012

Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by NRG-2

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,838
App. No.
11/085,812
Granted
Feb 14, 2012
Kind
B2
Abstract

The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.

Claims (7)

1. A method for protecting dopaminergic neurons from damage, said method comprising: contacting the dopaminergic neurons with a recombinant NRG-2 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:4 in an amount that promotes survival of dopaminergic neurons under stress.

2. The method of claim 1 where the dopaminergic neuron is a midbrain dopaminergic neuron.

3. The method of claim 1 where the stress is oxidative stress.

4. A method for promoting mitogenesis and differentiation of oligodendrocyte progenitors or for promoting survival of oligodendrocytes, said method comprising:

administering a recombinant NRG-2 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:4 to the oligodendrocyte progenitors or oligodendrocytes, wherein said administering elicits mitogenesis and differentiation of oligodendrocyte progenitors or promotes survival of oligodendrocytes.

5. The method of claim 4 wherein the administering step comprises administering the recombinant NRG-2 polypeptide to oligodendrocytes.

6. The methods of claim 4 wherein the administering step comprises administering the recombinant NRG-2 polypeptide to oligodendrocyte progenitors.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →